Wednesday, December 17, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Pebblebrook Hotel Trust: CEO Share Sale Coincides with Dividend Declaration

Andreas Sommer by Andreas Sommer
December 17, 2025
in Analysis, Dividends, Insider Trading, Real Estate & REITs
0
Pebblebrook Hotel Stock
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

Investors in Pebblebrook Hotel Trust are weighing two significant corporate announcements made public on the same day: a substantial stock sale by the company’s chief executive and the declaration of its quarterly dividend.

CEO Transaction and Shareholder Payout Details

Chairman and CEO Jon E. Bortz executed a sale of 50,000 common shares on December 15. The transaction was completed at a weighted average price of $11.263 per share, generating proceeds of approximately $563,150. Following this divestment, Bortz retains direct ownership of more than 1.55 million common shares, in addition to holdings of preferred stock and LTIP units.

Concurrently, the real estate investment trust announced its dividend schedule for the fourth quarter of 2025. A cash distribution of $0.01 per common share is scheduled for payment on January 15, 2026. The company also set regular quarterly dividend rates for its various series of preferred shares.

Should investors sell immediately? Or is it worth buying Pebblebrook Hotel?

Strategic Moves and Market Perspective

Pebblebrook’s recent strategy has focused on portfolio optimization. The firm has divested two hotel properties, located in Chicago and Beverly Hills, in transactions totaling over $116 million. Management has indicated that the proceeds are earmarked primarily for debt reduction and potential share repurchases.

Current analyst sentiment regarding the stock is largely neutral, with a consensus rating hovering around “Hold.” The average price target among market researchers falls within a narrow band, between $12.13 and $12.28 per share. Pebblebrook’s stock closed at $11.61 on December 15, positioning it within this target range.

The market now awaits the company’s 2025 quarterly and annual financial results, which are expected to provide crucial insight into its operational performance and future financial trajectory.

Ad

Pebblebrook Hotel Stock: Buy or Sell?! New Pebblebrook Hotel Analysis from December 17 delivers the answer:

The latest Pebblebrook Hotel figures speak for themselves: Urgent action needed for Pebblebrook Hotel investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 17.

Pebblebrook Hotel: Buy or sell? Read more here...

Tags: Pebblebrook Hotel
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

Gilead Sciences Stock
Analysis

Gilead Sciences Advances HIV Treatment with Promising Phase 3 Trial Results

December 17, 2025
Atlassian Stock
Analysis

Insider Selling Adds Pressure to Atlassian’s Struggling Shares

December 17, 2025
Clover Health Investments Registered (A) Stock
Analysis

Clover Health Investors Await Crucial Strategy Presentation

December 17, 2025
Next Post
Viking Therapeutics Stock

Viking Therapeutics Stock Consolidates as Market Awaits Next Catalyst

FirstCash Stock

FirstCash Shares: Assessing the Surge Amidst Valuation Concerns

QuantumScape Stock

QuantumScape Executives Capitalize on Share Gains Amid Operational Milestones

Recommended

Wabash National Stock

Wabash National Shares Face Sustained Decline

1 month ago
Pfizer Stock

Pfizer’s Narrow Vaccine Approval Presents Commercial Challenge

4 months ago
FirstCash Stock

FirstCash Shares Surge Following Exceptional Quarterly Performance

1 month ago
Laboratory of America Stock

Labcorp Shares Face Divergent Analyst Views Amid Growth Strategy

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Clover Health Investors Await Crucial Strategy Presentation

SunHydrogen Shares Face Mounting Technical Pressure

Cardano’s Critical Juncture: Technical Gains Clash With Market Realities

Brazilian Airline Gol Faces Legal Hurdle in Bankruptcy Proceedings

Bloom Energy Shares Face a Reality Check as AI Infrastructure Costs Soar

Dow Jones Consolidates Following Record Peak

Trending

Quantum Computing Stock
AI & Quantum Computing

Quantum Computing Stock Pivots with Major Acquisition

by Dieter Jaworski
December 17, 2025
0

The quantum computing sector is witnessing a strategic shift as Quantum Computing moves to acquire Luminar Semiconductor....

Gilead Sciences Stock

Gilead Sciences Advances HIV Treatment with Promising Phase 3 Trial Results

December 17, 2025
Atlassian Stock

Insider Selling Adds Pressure to Atlassian’s Struggling Shares

December 17, 2025
Clover Health Investments Registered (A) Stock

Clover Health Investors Await Crucial Strategy Presentation

December 17, 2025
SunHydrogen Stock

SunHydrogen Shares Face Mounting Technical Pressure

December 17, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Quantum Computing Stock Pivots with Major Acquisition
  • Gilead Sciences Advances HIV Treatment with Promising Phase 3 Trial Results
  • Insider Selling Adds Pressure to Atlassian’s Struggling Shares

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com